The Current Ratio as of September 2024 (TTM) for Immunome, Inc. (IMNM) is 7.12

According to Immunome, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.12. This represents a change of 2.18% compared to the average of 6.97 of the last 4 quarters.

Immunome, Inc. (IMNM) Historical Current Ratio (quarterly & annually)

How has IMNM Current Ratio performed in the past?

The mean historical Current Ratio of Immunome, Inc. over the last ten years is 5.48. The current 7.12 Current Ratio has changed 12.90% with respect to the historical average. Over the past ten years (40 quarters), IMNM's Current Ratio was at its highest in in the June 2021 quarter at 17.84. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Immunome, Inc. (IMNM) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Immunome, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Immunome, Inc. (IMNM) Average Current Ratio

How has IMNM Current Ratio performed in the past?

The current Current Ratio of Immunome, Inc. (IMNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Immunome, Inc. (IMNM) Current Ratio vs. Peers

How is IMNM’s Current Ratio compared to its peers?

Immunome, Inc.’s Current Ratio is greater than Anebulo Pharmaceuticals, Inc. (5.32), greater than Adagene Inc. (2.50), less than Acrivon Therapeutics, Inc. Common Stock (16.16), less than AnaptysBio, Inc. (9.09), less than Mineralys Therapeutics, Inc. (11.20), less than Molecular Partners AG (14.58), less than MediciNova, Inc. (18.24), greater than Champions Oncology, Inc. (0.69), less than Cyteir Therapeutics, Inc. (21.89), greater than Aerovate Therapeutics, Inc. (6.51), less than Rezolute, Inc. (11.82), less than AN2 Therapeutics, Inc. (10.61), greater than Gain Therapeutics, Inc. (2.84), greater than TFF Pharmaceuticals, Inc. (1.63), greater than aTyr Pharma, Inc. (6.07), greater than IN8bio, Inc. (2.66), less than Lantern Pharma Inc. (7.67), less than Ikena Oncology, Inc. (18.22), less than Celcuity Inc. (14.95),

Build a custom stock screener for Immunome, Inc. (IMNM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunome, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immunome, Inc. (IMNM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immunome, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.